Who is sponsoring NCT06005402?

NCT06005402 is sponsored by Cessation Therapeutics, Inc..

What condition does NCT06005402 study?

NCT06005402 studies Opioid Overdose, Opioid Use Disorder.

What drugs are being tested in NCT06005402?

Interventions: CSX-1004, Placebo.

What is the status of NCT06005402?

NCT06005402 is currently COMPLETED.

Last reviewed 2024-08-21 · How we verify

Safety, Tolerability, and Pharmacokinetics of CSX-1004

NCT06005402 PHASE1 COMPLETED

This is a Phase 1a, randomized, double-blind, single ascending dose study, designed to assess the safety, tolerability, and PK of a single CSX-1004 injection, administered by IV infusion across a range of doses in healthy adult subjects. The study will have 3 phases: Screening, Inpatient Treatment, and Outpatient Follow-up. The primary objective of the study is to determine the safety and tolerability of CSX-1004 Injection administered by intravenous (IV) infusion across a range of doses in healthy adult subjects. The secondary objective of the study is to determine the pharmacokinetics (PK) of CSX-1004 Injection administered by IV infusion across a range of doses in healthy adult subjects.

Details

Lead sponsor	Cessation Therapeutics, Inc.
Phase	PHASE1
Status	COMPLETED
Enrolment	32
Start date	Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Opioid Overdose
Opioid Use Disorder

Interventions

CSX-1004
Placebo

Countries

United States